---
document_datetime: 2025-03-28 16:33:16
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/lydisilka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: lydisilka-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 5.2630993
conversion_datetime: 2025-12-31 01:32:33.513056
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Lydisilka

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                                                                                                                                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                                                                                                                                                                                                  |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026              | Update of sections 4.2, 5.1 and 5.2 of the SmPC in order to update information on paediatric population based on results from study MIT-Es001-C303. This is a phase 3, open-label, single-arm study to evaluate the safety, compliance and pharmacokinetics associated with the use of a combined oral | 30/01/2025                          | 26/02/2025                                  | SmPC and PL                      | In a phase 3 study including adolescents aged 12 to-17 years, the product was well-tolerated and no safety concerns were raised during the study. The contraceptive efficacy is expected to be the same in post-menarchal adolescents compared to users 18 years and older. There is no relevant use of Drovelis in pre- |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|           | contraceptive containing 15 mg estetrol monohydrate and 3 mg drospirenone in post- menarchal female adolescents for 6 cycles. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                                                                                                            |            |            |             | menarcheal adolescents. For more information, please refer to the Summary of Product Characteristics.   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|---------------------------------------------------------------------------------------------------------|
| II/0025   | Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding renal impairment based on final results from study MIT-Do001-C103. This is a Phase 1, open-label, sequential group, single-dose study to evaluate the pharmacokinetics and safety of estetrol monohydrate (E4) in female subjects with varying degrees of renal function. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance | 12/12/2024 | 26/02/2025 | SmPC and PL |                                                                                                         |
| IA/0027/G | This was an application for a group of variations. B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer                                                                             | 28/06/2024 | n/a        |             |                                                                                                         |

<div style=\"page-break-after: always\"></div>

| PSUSA/10938 /202311   | Periodic Safety Update EU Single assessment - drospirenone / estetrol                                                                                                                                                                                                                                                                                                                                                                                           | 13/06/2024   | n/a        |                 | PRAC Recommendation - maintenance                                             |
|-----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------|-------------------------------------------------------------------------------|
| II/0021               | Update of sections 4.2 and 5.2 of the SmPC in order to update information regarding hepatic impairment based on final results from study MIT-Do001-C102; this is a Phase 1, open-label, parallel group, single- dose study to evaluate the pharmacokinetics and safety of estetrol (E4) in subjects with varying degrees of hepatic function. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 11/04/2024   | 26/02/2025 | SmPC            | For more information, please refer to the Summary of Product Characteristics. |
| IB/0023               | B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data                                                                                                                                                                                                                                                                                          | 07/02/2024   | n/a        |                 |                                                                               |
| IA/0022/G             | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                    | 07/12/2023   | 25/04/2024 | Annex II and PL |                                                                               |
| PSUSA/10938 /202305   | Periodic Safety Update EU Single assessment - drospirenone / estetrol                                                                                                                                                                                                                                                                                                                                                                                           | 30/11/2023   | n/a        |                 | PRAC Recommendation - maintenance                                             |

<div style=\"page-break-after: always\"></div>

| PSUSA/10938 /202211   | Periodic Safety Update EU Single assessment - drospirenone / estetrol                                                                                                                                                                                                        | 08/06/2023   | n/a        |             | PRAC Recommendation - maintenance   |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|-------------------------------------|
| IB/0018               | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                               | 30/03/2023   | 25/04/2024 | SmPC and PL |                                     |
| IAIN/0019             | B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer                                                                                      | 21/03/2023   | n/a        |             |                                     |
| IB/0016               | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                                | 03/03/2023   | n/a        |             |                                     |
| PSUSA/10938 /202205   | Periodic Safety Update EU Single assessment - drospirenone / estetrol                                                                                                                                                                                                        | 01/12/2022   | n/a        |             | PRAC Recommendation - maintenance   |
| IA/0015/G             | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure | 30/11/2022   | n/a        |             |                                     |
| IB/0014               | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale                                                                                                                                                                  | 29/11/2022   | n/a        |             |                                     |

<div style=\"page-break-after: always\"></div>

|           | (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |            |     |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| IB/0012   | B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 15/11/2022 | n/a |
| IB/0011/G | This was an application for a group of variations. B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.a.3.a - Change in batch size (including batch size ranges) of AS or intermediate - Up to 10-fold increase compared to the originally approved batch size B.I.a.2.e - Changes in the manufacturing process of the AS - Minor change to the restricted part of an ASMF B.I.b.1.h - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition or replacement (excl. Biol. or immunol. substance) of a specification parameter as a result of a safety or quality issue A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.a.1.a - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The proposed manufacturer is part of the same | 15/11/2022 | n/a |

<div style=\"page-break-after: always\"></div>

|             | B.I.b.1.d - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Deletion of a non- significant specification parameter (e.g. deletion of an obsolete parameter) B.I.a.1.i - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a new site of micronisation                                                                                                                                                                                                                                                               |            |     | manufacturer   |
|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|----------------|
| IAIN/0013/G | This was an application for a group of variations. B.III.1.a.1 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - New certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer B.III.1.a.2 - Submission of a new/updated or deletion of Ph. Eur. Certificate of Suitability to the relevant Ph. Eur. Monograph - Updated certificate from an already approved manufacturer | 18/10/2022 | n/a |                |
| IA/0009/G   | This was an application for a group of variations. B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor                                                                                                                                                                                                                                                                                                                                                                      | 25/07/2022 | n/a |                |

<div style=\"page-break-after: always\"></div>

|                     | changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                             |            |            |                 |                                                                                                                                                                                                                                            |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10938 /202111 | Periodic Safety Update EU Single assessment - drospirenone / estetrol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 10/06/2022 | n/a        |                 | PRAC Recommendation - maintenance                                                                                                                                                                                                          |
| IB/0008             | C.I.3.z - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Other variation                                                                                                                                                                                                                                                                                                                                                                     | 22/04/2022 | 29/09/2022 | SmPC and PL     | Update of Sections 4.4, 4.5 and 4.8 of the SmPC with wording based on PRAC recommendation formulated for PSUSA (PSUSA/00002182/202101) on nomegestrol/estradiol (CMDh meeting held on 12-14 October 2021). The PL was updated accordingly. |
| II/0006/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation | 31/03/2022 | 29/09/2022 | Annex II and PL |                                                                                                                                                                                                                                            |
| II/0004/G           | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 16/12/2021 | n/a        |                 |                                                                                                                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

| B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.z - Change in the specification parameters and/or limits of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.e.2.z - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Other variation B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.d - Change in the specification parameters   |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

|           | specification parameter B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.e.2.c - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Deletion of a non-significant specification parameter (e.g. deletion of an obsolete parameter)   |            |     | non-significant   |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-------------------|
| II/0001/G | This was an application for a group of variations. B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported an ASMF                                                                                                                                                                                                                                       | 09/12/2021 | n/a | by                |
| IAIN/0005 | B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 16/11/2021 | n/a |                   |

<div style=\"page-break-after: always\"></div>

| II/0003   | B.I.a.1.b - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Introduction of a manufacturer of the AS supported by an ASMF                                                                                                                                                                                                                                                          | 11/11/2021   | n/a        |             |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------|
| II/0002   | Update of section 5.3 of the SmPC following a revision of the Environmental Risk Assessment (ERA) in order to include the E4 PECsw based on a refined Fpen of 0.0044. In addition, the MAH has taken the opportunity to implement minor editorial changes in the SmPC, the Labelling and Package Leaflet. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 30/09/2021   | 29/09/2022 | SmPC and PL |